������Ƶ

Oxford, United Kingdom – December 7 2022 - ������Ƶ Limited, a private, clinical stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, announced today that Cosmo Feilding Mellen, Chief Executive Officer and Rob Conley, Chief Scientific Officer will be a panellist at Canaccord Genuity’s Symposium on New Paradigms and Treatment Approaches in Mental Health, taking place virtually on December 13th 2022.��

The panel, ‘Opportunities and challenges in changing the status quo on mental health’, will take place at 10am EST / 3pm GMT on the 13th December and will also feature COMPASS Pathway’s Chief Executive Officer, Kabir Nath and Chief Medical Officer, Guy Goodwin as well as Reunion Neuroscience’s Chief Executive Officer, Greg Mayes and Chief Scientific Officer, Nathan Bryson.��

For more information please contact: Charlotte Chorley, Communications Lead, info@beckleypsytech.com‍

������Ƶ - ��

������Ƶ Ltd is a private, clinical-stage biotechnology company dedicated to improving the lives of people suffering from neuropsychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. The Company’s most advanced programmes are focused on the development of BPL-003, an intranasal synthetic formulation of 5-MeO-DMT, for treatment resistant depression (TRD) and ELE-101, an intravenous synthetic formulation of psilocin, the active metabolite of psilocybin, for major depressive disorder (MDD). Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the ������Ƶ Foundation, ������Ƶ combines world-leading psychedelic science with deep drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden these conditions have on individuals and society.

‍